These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27197868)

  • 1. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study.
    Holz FG; Tadayoni R; Beatty S; Berger AR; Cereda MG; Hykin P; Staurenghi G; Wittrup-Jensen K; Nilsson J; Kim K; Sivaprasad S
    Eye (Lond); 2016 Aug; 30(8):1063-71. PubMed ID: 27197868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.
    Holz FG; Tadayoni R; Beatty S; Berger A; Cereda MG; Hykin P; Staurenghi G; Wittrup-Jensen K; Altemark A; Nilsson J; Kim K; Sivaprasad S
    Br J Ophthalmol; 2016 Dec; 100(12):1623-1628. PubMed ID: 27030279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis.
    Holz FG; Tadayoni R; Beatty S; Berger AR; Cereda MG; Hykin P; Hoyng CB; Wittrup-Jensen K; Altemark A; Nilsson J; Kim K; Sivaprasad S
    Ophthalmic Res; 2017; 58(1):49-55. PubMed ID: 27832661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
    Inan S; Baysal Z; Inan UU
    Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
    [No Abstract]   [Full Text] [Related]  

  • 5. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].
    Ziemssen F; Eter N; Fauser S; Bopp S; Radermacher M; Hasanbasic Z; Holz FG;
    Ophthalmologe; 2015 Mar; 112(3):246-54. PubMed ID: 25668709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision.
    Toth LA; Stevenson M; Chakravarthy U
    Retina; 2015 Oct; 35(10):1957-63. PubMed ID: 25946692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
    Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
    Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
    Zweifel SA; Saroj N; Shapiro H; Freund KB
    Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E; Rayess N; Ho AC; Regillo CD
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY; Kwon KY; Byeon SH
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration.
    Lee KH; Chin HS; Kim NR; Moon YS
    Korean J Ophthalmol; 2015 Dec; 29(6):396-403. PubMed ID: 26635456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
    Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab.
    Massamba N; Dirani A; Knoeri J; Pasquier B; Ingram A; Soubrane G
    Eye (Lond); 2015 Nov; 29(11):1453-7. PubMed ID: 26206530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment.
    Bloch SB; la Cour M; Sander B; Hansen LK; Fuchs J; Lund-Andersen H; Larsen M
    Acta Ophthalmol; 2013 Feb; 91(1):42-7. PubMed ID: 22008284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG
    Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.